Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Allergy Therapeutics (HHU) Stock Price & Analysis

HHU Stock Chart & Stats

€0.04€0.00(0.00%)
At close: 5:30 PM GMT+1
EUR 0.05EUR 0.06EUR 0.0724 Aug26 Aug30 Sep
Day’s Range
EUR 0.04 - EUR 0.04
52-Week Range
EUR 0.04 - EUR 0.16
Previous Close
EUR 0.04
Volume
0
Average Volume (3M)
4,779
Market Cap
EUR 302.84M
Enterprise Value
EUR 591.39M
Total Cash (Recent Filing)
EUR 10.08M
Total Debt (Recent Filing)
EUR 26.75M
Price to Earnings (P/E)
―
Beta
0.57
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized AIT Business Model

A focused specialty model in allergen immunotherapy creates durable competitive advantage: deep clinical expertise, regulatory know-how and therapy-specific manufacturing act as barriers to entry, supporting repeat prescribing and long-term customer relationships with healthcare providers.

Established European Regulated Footprint

A presence across regulated European markets supports stable reimbursement pathways and regulatory experience. That geographic focus reduces market-entry uncertainty, enables scale in core markets, and strengthens distributor and payer relationships over multiple regulatory cycles.

Broad AIT And Diagnostics Portfolio

Combining allergy vaccines with complementary diagnostics creates cross-sell opportunities and improves patient targeting. Integrated product sets increase clinical stickiness and can raise lifetime revenue per patient, supporting steadier commercial revenue streams over time.

Bears Say

Negative Shareholders' Equity

Negative equity and elevated leverage materially weaken the balance sheet, limiting capacity to absorb shocks and increasing refinancing and covenant risk. This structural fragility reduces strategic optionality and raises the likelihood of dilutive or costly financing over months.

Persistent Negative Cash Flow

Sustained negative operating and free cash flow undermines self-funding for R&D and commercial expansion. Large FCF deterioration forces reliance on external capital, elevating solvency risk and potentially constraining investment in manufacturing or new product development.

Declining Revenue And Heavy Losses

A structural decline in revenue combined with large net losses and negative margins indicates weak demand or margin pressure. Over months, this impedes scale economics, reduces reinvestment capacity, and makes reaching sustained profitability more challenging without strategic change.

Allergy Therapeutics News

HHU FAQ

What was Allergy Therapeutics’s price range in the past 12 months?
Allergy Therapeutics lowest stock price was €0.04 and its highest was €0.16 in the past 12 months.
What is Allergy Therapeutics’s market cap?
Allergy Therapeutics’s market cap is €302.84M.
When is Allergy Therapeutics’s upcoming earnings report date?
Allergy Therapeutics’s next earnings report is estimated for Sep 24, 2026 (not yet confirmed), which is 38 days ago.
How were Allergy Therapeutics’s earnings last quarter?
Allergy Therapeutics released its earnings results on Mar 31, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Allergy Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Allergy Therapeutics pay dividends?
Allergy Therapeutics does not currently pay dividends.
What is Allergy Therapeutics’s EPS estimate?
Allergy Therapeutics’s EPS estimate is -0.01.
How many shares outstanding does Allergy Therapeutics have?
Allergy Therapeutics has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics’s price movement after its last earnings report?
Allergy Therapeutics reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Allergy Therapeutics?
Currently, no hedge funds are holding shares in DE:HHU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology